Disclosure Of First-Time Adoption [Text Block]

Biotest AG - Filing #6464577

Concept	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	As at 2024-12-31	As at 2024-12-31	2024-01-01 to 2024-12-31	As at 2024-12-31	As at 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	As at 2024-12-31	2024-01-01 to 2024-12-31	As at 2024-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31
Disclosure of first-time adoption [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [abstract]
Disclosure of comparative information prepared under previous GAAP [line items]
Equity	—	—	2,745,000,000 EUR	2,198,000,000 EUR	—	396,000,000 EUR	53,000,000 EUR	—	—	5,307,000,000 EUR	—	85,000,000 EUR	115,000,000 EUR	—	—	4,989,000,000 EUR	2,498,000,000 EUR	—	—	—	2,198,000,000 EUR	—	396,000,000 EUR	11,000,000 EUR	3,711,000,000 EUR	95,000,000 EUR	2,198,000,000 EUR	1,232,000,000 EUR	396,000,000 EUR	20,000,000 EUR
Comprehensive income	– EUR	– EUR	—	—	42,000,000 EUR	—	—	264,000,000 EUR	336,000,000 EUR	—	30,000,000 EUR	—	—	1,278,000,000 EUR	20,000,000 EUR	—	—	1,267,000,000 EUR	– EUR	31,000,000 EUR	—	– EUR	—	—	—	—	—	—	—	—
Profit (loss)	– EUR	– EUR	—	—	– EUR	—	—	264,000,000 EUR	264,000,000 EUR	—	– EUR	—	—	1,270,000,000 EUR	– EUR	—	—	1,270,000,000 EUR	– EUR	– EUR	—	– EUR	—	—	—	—	—	—	—	—